Abbott and iCardio.ai Collaborate on Artificial Intelligence Algorithms for Imaging Applications

iCardio.ai Press Release

September 16, 2024--Today iCardio.ai is announcing a collaboration with Abbott to develop artificial intelligence applications for its imaging devices. The collaboration is driven by Abbott's commitment to innovation in healthcare and is aimed at accelerating the integration of artificial intelligence into its electrophysiology imaging product line, which is a critical tool used in treating patients battling cardiac arrhythmias like atrial fibrillation.

‍iCardio.ai will support Abbott’s goals of automating model creation on the company’s EnSite X cardiac mapping system using 2D intracardiac echo (ICE) images captured by Abbott’s ICE catheters.

"We are honored to begin collaborating with Abbott, a well-recognized and global health care company. The collaboration will take advantage of iCardio.ai's internal capabilities and in-house talents. This work with Abbott is aligned with our mission of bringing artificial intelligence to ultrasound," says Joseph Sokol, CEO of iCardio.ai. "This new focus reflects the continued progress of our organization."

To learn more or to get in touch with our organization, reach out to humans@icardio.ai.

About iCardio.ai

iCardio.ai is a Los Angeles-based company that develops machine learning and deep learning algorithms for the analysis of ultrasound applications, with a specific focus on transthoracic echo. Leveraging a database of over +200M images, iCardio.ai is bringing AI to echocardiography.